Treatment of childhood sarcoma with irinotecan: Bilirubin level as a predictor of gastrointestinal toxicity

Journal of Chemotherapy

Volumn 21, Issue 6, 2009, Pages 693-697

  Ruggiero, Antonio ^a   Coccia, P ^a   Scalzone, M ^a   Attina G ^a   Riccardi, R ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Diarrhea; Gastrointestinal toxicity; Irinotecan; Sarcoma

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIEMETIC AGENT; BILIRUBIN; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; LOPERAMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ABDOMINAL CRAMP; ADOLESCENT; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DIARRHEA; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUID THERAPY; GASTROINTESTINAL TOXICITY; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT MONITORING; PREDICTION; PRESCHOOL CHILD; RANK SUM TEST; SARCOMA; SCHOOL CHILD; VOMITING; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; INFANT; INTESTINE MUCOSA; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SOFT TISSUE TUMOR; STOMACH MUCOSA;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIRUBIN; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DIARRHEA; FEMALE; GASTRIC MUCOSA; HUMANS; INFANT; INTESTINAL MUCOSA; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 77649322462     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.6.693     Document Type: Article

References (19)

1. Bisogno G, Riccardi R, Ruggiero A, Arcamone G, Prete A, Surico G, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006; 106 (3): 703-707.
2. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, et al. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res 2001; 7: 32-37.
3. Bomgaars L, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer 2006; 46: 50-55.
4. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999; 17: 1815-1824.
5. Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 2003; 21: 3844-3852.
6. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997; 33: 245-259.
7. Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, et al. Phase I and pharmacologic study of irinotecan administered as a 96- hour infusion weekly to adult cancer patients. J Clin Oncol 2000; 18: 659-667.
8. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity. A pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
9. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255-269.
10. Takeuchi K, Kobayashi Y, Tamaki S, Ishihara T, Maruo Y, Araki J, et al. Genetic polymorphisms of bilirubin uridine diphos phate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol 2004; 19: 1023-1028.
11. Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008; 34 (7): 656-669.
12. de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, Sparreboom A, et al. Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 2008; 84(2): 254-262.
13. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27(16): 2604-2614.
14. Liu CY, Chen PM, Chiou T, Liu J, Lin JK, Lin TJ,et al. UGT1A1*28 polymorphism predicts Irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008; 112: 1932-1940.
15. Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, et al. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemother Pharmacol 2008; 62(6): 1027-1037.
16. Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol. 2007; 25(18): 2594-2600.
17. Yamamoto M, Kurita A, Asahara T, Takakura A, Katono K, Iwasaki M, et al. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rat. Oncol Rep 2008; 20(4): 727-730.
18. Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-ll)-induced diarrhea. Cancer Res 2002; 62(1): 179-187.
19. Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 2002; 62(20): 5778-5784.